LLY Jan 2025 1280.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

8.80

0.00

(0.00%)

As of 10:55AM EDT. Market open.

Loading interactive chart…

PR Newswire
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Investor's Business Daily
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
Tesla drove the S&P 500 and Nasdaq to highs, though small caps fell for the week. Cooling economic data raised rate-cut hopes.
Zacks
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.